Fresenius Kabi introduces pegfilgrastim biosimilar for cancer patients in US

Stimufend is a leukocyte growth factor that is indicated for reducing the incidence of infection in patients with non-myeloid malignancies. Credit: Fresenius Kabi AG / Business Wire.